Ascendis Pharma Growth Disorders A/s
Clinical trials sponsored by Ascendis Pharma Growth Disorders A/s, explained in plain language.
-
New combo therapy aims to boost growth in kids with dwarfism
Disease control OngoingThis study tests whether two weekly injections, navepegritide and lonapegsomatropin, can safely improve growth in children aged 2 to 11 with achondroplasia (a common form of dwarfism). The trial involves 22 children and lasts 156 weeks. The goal is to see if the combination works…
Phase: PHASE2 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Weekly shot shows promise for helping kids with dwarfism grow
Disease control ENROLLING_BY_INVITATIONThis study tests a once-weekly injection called TransCon CNP in children and teens with achondroplasia, the most common form of dwarfism. The goal is to see if it is safe and helps improve growth over several years. Participants who were in a previous TransCon CNP trial can join,…
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated May 06, 2026 16:02 UTC